Kromek Group PLC Kromek awarded new DARPA bio-threat contract (7174B)
June 14 2021 - 2:00AM
UK Regulatory
TIDMKMK
RNS Number : 7174B
Kromek Group PLC
14 June 2021
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF EU REGULATION 596/2014 (WHICH FORMS PART OF
DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT
2018). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE
INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
14 June 2021
Kromek Group plc
("Kromek" or the "Group")
Kromek awarded c. $6m contract by DARPA to further develop its
bio-threat detection system
Phase II to further develop the functionality of technology to
detect and identify pathogens and include a networked solution
Kromek (AIM: KMK), a worldwide supplier of detection technology
focusing on the medical, security screening and nuclear markets, is
pleased to announce that it has been awarded a new c. $6m contract
by the Defense Advanced Research Projects Agency ("DARPA"), an
agency of the US Department of Defense, for Phase II of its
development of a biological threat detection system that senses,
analyses and identifies airborne pathogens. Kromek will deliver the
contract over the next 28-month period, commencing immediately.
Phases I and II are an extension of the existing SIGMA network
for biological threats as part of DARPA's SIGMA+ initiative. Phase
II follows the successful completion of Phase I where key
milestones achieved over the past two years included the
development of a vehicle-mounted biological-threat identifier as
well as a miniaturised mobile wide-area bio-surveillance system.
This new contract takes the overall programme value awarded to
Kromek to c. $13m.
Phase II will seek to deliver a completely automated wide
spectrum airborne pathogen detection system that is fully mobile
and runs autonomously. Also, systems will be designed to be
networked where data is stored, shared and further analysed and
provide real-time information to decision makers. Key milestones
under Phase II include the creation of beta units as well as final
design and build of systems for extended field trials. In addition
to the design process, the bioinformatics methodologies will be
refined as data is collected for both enhanced performance and
increased speed.
Dr Arnab Basu, CEO of Kromek, said: "In addition to the
ever-present danger of bio-terrorism, the outbreak of the pandemic
has exposed the world to the severity of biological threats and
their potential impact on public health and the global economy, and
has demonstrated the need to rapidly evolve bio-security systems
and associated technologies. This contract will allow us to
continue our work in developing a mobile wide-area bio-surveillance
system capable of detecting airborne pathogens in real-time. We
look forward to reporting on our progress as we deliver on our
milestones."
Approved for Public Release, Distribution Unlimited
For further information, please contact:
Kromek Group plc
Arnab Basu, CEO
Paul Farquhar +44 (0)1740 626 060
Cenkos Securities plc (Nominated Adviser
and Broker)
Max Hartley/Camilla Hume (NOMAD)
Julian Morse (Sales) +44 (0)20 7397 8900
Luther Pendragon (PR)
Harry Chathli
Claire Norbury +44 (0)20 7618 9100
About Kromek Group plc
Kromek Group plc is a technology group (global HQ in County
Durham) and a leading developer of high performance radiation
detection products based on cadmium zinc telluride ("CZT") and
other advanced technologies. Using its core technology platforms,
Kromek designs, develops and produces x-ray and gamma ray imaging
and radiation detection products for the medical, security
screening and nuclear markets.
The Group's products provide high resolution information on
material composition and structure and are used in multiple
applications, ranging from the identification of cancerous tissues
to hazardous materials, such as explosives, and the analysis of
radioactive materials.
The Group's business model provides a vertically integrated
technology offering to customers, from radiation detector materials
to finished products or detectors, including software, electronics
and application specific integrated circuits ("ASICs").
The Group has operations in the UK and US (California and
Pennsylvania), and is selling internationally through a combination
of distributors and direct OEM sales.
Currently, the Group has over 150 full-time employees across its
global operations. Further information on Kromek Group is available
at www.kromek.com and
https://twitter.com/kromekgroup.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTFJMMTMTBBTPB
(END) Dow Jones Newswires
June 14, 2021 02:00 ET (06:00 GMT)
Kromek (LSE:KMK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kromek (LSE:KMK)
Historical Stock Chart
From Jul 2023 to Jul 2024